3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Other
1
Myeloid
1
Lymphoid
1
Conditions
Lymphoma, Non-Hodgkin
2
Hodgkin Disease
2
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Mucositis
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Interventions
Cyclophosphamide
172
fludarabine phosphate
132
Tacrolimus
100
Mycophenolic Acid
92
fludarabine
90
Busulfan
88
Whole-Body Irradiation
83
Peripheral Blood Stem Cell Transplantation
77
Antilymphocyte Serum
71
Melphalan
69
Filgrastim
63
Cyclosporine
62
Methotrexate
54
Radiotherapy
40
Thiotepa
39
Cord Blood Stem Cell Transplantation
35
Granulocyte Colony-Stimulating Factor
34
Stem Cell Transplantation
32
thymoglobulin
29
Sirolimus
27
Methylprednisolone
26
Rituximab
24
Cytarabine
23
Clofarabine
23
Etoposide
22
Alemtuzumab
20
Azacitidine
17
Specimen Handling
14
Cyclosporins
13
sargramostim
12
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Myelodysplastic Syndromes
×
angiotensin I (1-7)
×
Lymphoid
×
Clear all
NCT01300611
2020-12-08
USBTXA127CBT
Tarix Pharmaceuticals
Phase 1
Terminated
20 enrolled